New PHASE Scientific order boosts Lumos Diagnostics’ US foothold, driving rapid test revenue growth and positioning the firm as a key player in global point‑of‑care diagnostics.
Explore how Lumos Diagnostics’ performance-rights securities were discontinued—yet the company’s point‑of‑care diagnostics and ASX trading remain robust.